Neonatal Klebsiella pneumonia sepsis and imipenem/cilastatin

被引：11

作者：

Oral R.

Akisü M. ^{[3
]}

Kültürsay N. ^{[2
]}

Vardar F. ^{[1
]}

Tansuĝ N. ^{[2
]}

机构：

[1] Ege University Medical Faculty, Izmir

[2] Department of Pediatrics, Division of Neonatology, Pediatric Infectious Diseases, Izmir

[3] Ege University Medical Faculty, Department of Pediatrics, Bornova 35100, Izmir

来源：

The Indian Journal of Pediatrics | 1998年 / 65卷 / 1期

关键词：

Imipenem; Klebsiella pneumonia; Newborn; Sepsis;

D O I：

10.1007/BF02849703

中图分类号：

学科分类号：

摘要：

Efficacy and safety of imipenem/cilastatin in neonatal ]Klebsiella pneumonia sepsis was investigated in 45 infants compared to 39 control infants on conventional antibiotic regimen. Sensitivity to imipenem was 94% followed by cephoxitin (88%), quinolons (80%), and amikacin (52%) according to susceptibility results in the study group. Treatment duration of surviving infants was 16.5 ± 4.6 and 20.3 ± 6.4 days in the study and control groups respectively (p < 0.05). Five infants (11%) vs 27 (69%) were unresponsive (septic deaths) to treatment in the study and control groups respectively (p < 0.001). The cure rates were 73% and 28% respectively (p < 0.001). Sequelae free discharge rates were 67% and 23% respectively (p < 0.001). The most frequent adverse effects of imipenem/cilastatin were Candida albicans superinfection (20%); Candida albicans colonisation (10%); impairment of liver and renal functions (19% and 10% respectively); seizures (5%); thrombocytosis (3%); thrombophlebitis (3%); urine discoloration (3%); and Stapylococcus epidermidis colonisation (2%). Imipenem is considered a good alternative for neonatal Klebsiella pneumonia sepsis with these results, however, one must be aware of the increased risk of Candida albicans superinfection.

引用

页码：121 / 129

页数：8

共 25 条

[1]

Gotoff, S.P., Infections of the neonatal infant (1996) Textbook of Pediatrics, pp. 514-1450. , Beharman RE, Kliegman RM, Arvin AM. eds. Philadelphia : W.B. Saunders Colmpany

[2]

Toltzis, P., Blumer, J.L., Antibiotic resistant gram-negative bacteria in the critical care setting (1995) Pediatr Clin North Am, 42, pp. 687-702

[3]

Arvas, A., Perk, Y., Gür, E., Ilter, Ö., 1989-1992 yillari arasinda Yenidogan Ünitesinde izlenen bebeklerde infeksiyon dagilimi (1993) Proceedings of XXX. Turkish Pediatric and II, pp. 37-39. , National neonatology Congress, June 14-18th, Istanbul

[4]

Oygür, N., Yenidogan Ünitesinde Nozokomiyal infeksiyonlarin yillara göre dagilimi (1993) Proceedings of XXX. Turkish Pediatrics and II, pp. 33-34. , National Neonatolgy Congress, June 14-18th, Istanbul

[5]

Satar, M., Atici, A., Yilmaz, M., Yenidogan Ünitesinde Hastane Infeksiyonlari (1993) Proceedings of XXX. Turkish Pediatrics and II, pp. 40-42. , National Neonatology Congress, June 14-18th, Istanbul

[6]

Ertogan, F., Arsan, S., Nozokomiyal infeksiyonlar (1988-1992) (1993) Proceedings of XXX. Turkish Pediatrics and II, pp. 35-36. , National Neonatology Congress, June 14-18th, Istanbul

[7]

Kültürsay, N., Kütükcüler, N., Tansug, N., Kutlu, O., Etiology, treatment and prognosis of early-onset and nosocomial septicemia in neonatal intensive care unit (1995) Annals Med Scien, 4, pp. 1-7

[8]

Kültürsay, N., Tansug, N., Kütükçüler, N., Tokbas, A., Kutlu, O., Ceftazidime treatment in severe neonatal infections (1995) Annals Med Scien, 4, pp. 8-12

[9]

Freij, B.J., McCracken, G.H., Olsen, K.D., Threlkeld, N., Pharmacokinetics of imipenem-cilastatin in neonates (1985) Antimicrob Ag Chemother, 27, pp. 431-435

[10]

Buckley, M.M., Brogden, R.N., Barradell, L.B., Goa, K.L., Imipenem-cilastatin (1992) Drugs, 44, pp. 408-444

← 1 2 3 →